Study Evaluating Etanercept in Moderate to Severe Asthma

Completed · Phase 2

Conditions studied: Asthma

In brief

The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.

Key facts

Study ID

NCT00141791

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

120

Starts

2005-05-01

Expected to finish

2006-07-01

Last updated by the study team

2009-08-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe persistent asthma for at least 1 year
• Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
• Subjects must be on a high-dose inhaled corticosteroid (ICS)

You may not qualify if…

• Previous treatment with etanercept
• Current use of cigarettes
• Significant concurrent medical conditions at the time of screening

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Denver, Colorado, United States
• Study site — Sarasota, Florida, United States
• Study site — Tallahassee, Florida, United States
• Study site — Valrico, Florida, United States
• Study site — Covington, Louisiana, United States
• Study site — Wheaton, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Rockville Centre, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Portland, Oregon, United States
• Study site — Richmond, Virginia, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.